Bio-Rad Laboratories is slashing 5% of its staff, including over 100 in its Bay Area hometown, amid struggles in the biotech ...

Reports Q4 revenue $667.5M, consensus $679.75M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, commented: “Bio-Rad demonstrated ...

Laboratories “announced that the company has entered into a binding offer to purchase all equity interests in Stilla ...

Q4 2024 Earnings Call Transcript February 13, 2025 Bio-Rad Laboratories, Inc. beats earnings expectations. Reported EPS is $2.9, expectations were $2.86. Operator: Thank you for standing by. My name ...

Bio-Rad projects 2025 currency-neutral revenue growth of 1.5%-3.5%, excluding contributions from acquisitions. Diagnostics revenue is expected to grow between 2%-3%, while Life Science revenue is ...

At this time, I would like to welcome everyone to the Bio-Rad Fourth Quarter and Full Year 2024 Results Conference Call and Webcast. All lines have been placed on mute to prevent any background noise.

Bio-Rad Laboratories' cost-cutting plans come as the company swung to a loss in the fourth quarter amid lower sales across its life-science segment. The company posted a net loss of $715.8 million, or ...

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst expectations, sending shares down 4% in after-hours trading Thursday.

The decision to form a fruiting body have been studied extensively, however, the mechanical events that trigger the creation of multiple cell layers is poorly understood. Here the authors find M.

After hours: February 14 at 7:59:57 PM EST Loading Chart for U ...